OBS in Adolescent and Adults with EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study with an Open Label Extension

Overview

About this study

This is a clinical trial to test an experimental drug for the treatment of Eosinophilic Esophagitis (EoE)

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Males and Females, age 11-40
  • Histologic evidence of EoE
  • History of clinical symptoms of EoE including dysphagia
  • Willing to continue with dietary, environmental or medical therapy
  • Ability to read and understand english
  • Written Consent

Exclusion Criteria:

  • Any Medical condition that may compromise the safety of the subjects or interfere with the signs and symptoms of EoE
  • Use of immunomodulatory therapy
  • Current use of swallowed corticosteroids
  • Esophageal strictures,varices or upper GI bleed
  • Other current diseases of the GI tract
  • Current viral infection or immunodeficiency condition
  • Pregnancy
  • Hypersensitivity to budesonide
  • History of non compliance

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

David Katzka, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions